Pharsight

Arcutis patents expiration

1. Zoryve patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884050 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US9907788 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US10940142 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US11793796 ARCUTIS Inhibition of crystal growth of roflumilast
Jun, 2037

(13 years from now)

US11819496 ARCUTIS Topical roflumilast formulation having improved delivery and plasma half-life
Jun, 2037

(13 years from now)

US11129818 ARCUTIS Topical roflumilast formulation having improved delivery and plasma half life
Aug, 2037

(13 years from now)

US11707454 ARCUTIS Topical roflumilast formulation having antifungal properties
Dec, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Oct 5, 2026
New Product (NP) Jul 29, 2025

Drugs and Companies using ROFLUMILAST ingredient

Market Authorisation Date: 29 July, 2022

Treatment: Topical treatment of seborrheic dermatitis in patients 9 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

ZORYVE family patents

Family Patents